{"doi":"10.1101/2020.01.10.20016741","title":"Differences in Plasma Metabolites Related to Alzheimer’s Disease, APOE-ε4 status and Ethnicity","abstract":"Abstract INTRODUCTION We investigated metabolites in plasma to capture systemic biochemical changes associated with Alzheimer’s disease (AD). METHODS Metabolites in plasma were measured in 59 AD cases and 60 healthy participants of African American (AA), Caribbean Hispanic (CH) and non-Hispanic white (NHW) ancestry using untargeted liquid-chromatography based ultra-high resolution mass spectrometry. Metabolite differences between AD and healthy, ethnic groups and APOEε4 status were analyzed. Untargeted network analysis identified pathways enriched in AD-associated metabolites. RESULTS 5,929 annotated metabolites were measured. PLS-DA analysis inferred that AD clustered separately from healthy controls (AUC=0.9816); discriminating pathways included glycerophospholipid, sphingolipid and non-essential amino acid (alanine, aspartate, glutamate) metabolism. Metabolic features in AA clustered differently from CH and NHW (AUC=0.9275), and differed between APOE ε4-carriers and non-carriers (AUC=0.9972). DISCUSSION Metabolites, specifically lipids, were associated with AD, APOE ε4 and ethnic group. Metabolite profiling could identify perturbed AD pathways, but genetic and ancestral background need to be considered.","journal":"medRxiv","year":2020,"id":126131,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9372,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":256014,"name":"Vrinda Kalia","orcid":"0000-0003-2244-6663","position":1,"is_corresponding":false},{"id":49960,"name":"Jennifer J. Manly","orcid":"0000-0002-9481-7497","position":2,"is_corresponding":false},{"id":270469,"name":"Adam M. Brickman","orcid":"0000-0002-5125-8226","position":3,"is_corresponding":false},{"id":413237,"name":"Dolly Reyes‐Dumeyer","orcid":"0000-0003-3572-8248","position":4,"is_corresponding":false},{"id":413238,"name":"Rafael Lantigua","orcid":"0000-0003-4854-7331","position":5,"is_corresponding":false},{"id":104430,"name":"Iuliana Ionita‐Laza","orcid":"0000-0002-9001-2026","position":6,"is_corresponding":false},{"id":231483,"name":"Dean P. Jones","orcid":"0000-0002-2090-0677","position":7,"is_corresponding":false},{"id":87740,"name":"Gary W. Miller","orcid":"0000-0001-8984-1284","position":8,"is_corresponding":false},{"id":27608,"name":"Richard Mayeux","orcid":"0000-0001-6519-9696","position":9,"is_corresponding":false},{"id":63303,"name":"Badri N. Vardarajan","orcid":"0000-0002-5560-4085","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-18T23:15:23.509897Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}